|  |  |
| --- | --- |
|  | elshimaa.arafa@pharm.bsu.edu.eg  [shaimaarafa@yahoo.com](mailto:shaimaarafa@yahoo.com)  Mobile: +201000553032  Website: [www.researchgate.net/profile/El-Shaimaa\_Arafa/](http://www.researchgate.net/profile/El-Shaimaa_Arafa/info?ev=prf_info) |

# **El-Shaimaa Arafa, Ph.D**

## **Personal Data**

|  |  |
| --- | --- |
| *Nationality* | **Egyptian** |
| *Date of Birth* | **23 October 1975** |
| *Contact address* | **15 Street #10, Apt. #3, Maadi, Cairo** |

## **Education**

**2009** **Foreign Pharmacy Graduate Equivalency Certificate, FPGEC, USA**

The FPGEC Certification Program evaluates the qualifications of foreign pharmacy graduates in accordance with USA standards for pharmacy education.

**2005 – 2009** **Ph.D, Cairo University & The Ohio State University**

Ph.D degree in Pharmacology, Cairo Univ., Cairo, Egypt and The Ohio State Univ., Columbus, OH, USA (Sponsored by the scholar exchange program of the Egyptian Ministry of Higher Education). Title: “Molecular Mechanisms of Modulatory effects of Naturally Occurring Compounds on the Efficacy of Cancer Therapy”.

**1999 – 2005** **M.Sc., Cairo University, Faculty of Pharmacy**

Master degree of pharmaceutical sciences, Pharmacology and Toxicology. Title: “Comparative evaluation of the effectiveness of certain gastropathy-preventing drugs against experimentally-induced hyperacidity in animals”.

**1998 – 2000** **Pre-Master Courses, Cairo University, Faculty of Pharmacy**

Successfully completed the general Pre-Master courses (Statistics, Computer Sciences, and English Language) and special courses of Pharmacology and Toxicology department (Pathophysiology, Immunopharmacology, Bioassay, Toxicometrics) with a general grade of "Very Good"

**1993 – 1998** **B.Sc., Cairo University, Faculty of Pharmacy**

Bachelor degree of Pharmaceutical Sciences with a general grade of "Excellent With Honors”, GPA 3.96 on 4.0 scale

## **Other Postgraduate Courses**

## **Successfully Completed The Ohio State University Courses of:**

## Molecular Biology

## Molecular Pharmacology and Human Disease

## Biomedical Science Laboratory Techniques

## Animal Care and Ethical Considerations

## Occupational Health and Safety

## Radiation Safety

## Bloodborne Pathogens

## Toxicology Training

## Biological Safety Training for BSL2

## **Successfully Completed The Cairo University Courses of:**

## Use of Current Technology in Teaching

## Communication Skills

## Preparation of Faculty and Leadership members

## International Publishing of Scientific Research

## Managing Time and Meetings

## **Work & Research Experience**

|  |  |
| --- | --- |
| *2015– present*  *2009 – 2014* | **Associate Professor**  Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Egypt.  **Assistant Professor**  Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Egypt. |
| *2009 – 2010* | **Postdoctoral Research Associate**  The Ohio State University, Department of Radiology, Division of Radiobiology, Columbus, Ohio, USA |
| *2006 – 2008* | **Visiting Scholar**  The Ohio State University, Columbus, Ohio, USA, under the scholar exchange program of the Egyptian Ministry of Higher Education to obtain the PhD |
| *2005 – 2006* | **Assistant Lecturer**  Department of Pharmacology and Toxicology at Cairo University, Faculty of Pharmacy, Beni-Suef campus, Egypt |
| *1999 – 2005* | **Instructor and teaching assistant of Pharmacology & Toxicology**  Faulty of Pharmacy, Cairo University, Beni-Suef campus, Egypt. |

## **Teaching Experinence**

## **Participated in teaching the following classes organized by the Pharmacology and Toxicology Department For:**

## **Graduate pharmacy students:**

## Pathophysiology

## Pharmacometrics

## Toxicometrics

## Experimental Pharmacology

## Clinical Pharmacology

## Pharmacology and natural products

## **Undergraduate Pharmacy Students:**

## Basic pharmacology

## Toxicology

## Drug Interactions

## Therapeutics

## Clinical Pharmacology

## Bioassay and Biostatistics

## First Aid

## Medical Terminology

## **Skills & Activities**

|  |  |
| --- | --- |
| *Research Skills* | Cancer Biology, Cell Signaling, Cancer Chemoprevention, Translational Cancer Research, Clinical Toxicology, Cell Culture, Western blot, PCR, Electrophoresis, Gene Expression, Apoptosis, Molecular Mechanisms of Pharmacological Action, In Vitro Pharmacology, Clinical Pharmacology, Medicinal Plants and Herbs. |
| *Languages* | Arabic (native)  English (fluent)  French (fluent) |
| *Scientific Memberships* | American Association for Cancer Research (AACR)  The General Syndicate of Pharmacists in Egypt  The Egyptian Association of Pharmacists |
| *Interests* | Molecular mechanisms of natural anticancer drugs  Molecular pharmacology as a basis for drugs development  Oxidative stress implication in the pathophysiology of clinical disorders |

## **Journal Publications**

1. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Patnaik S, Zhao Q, **Arafa el-S**, Barakat B, Mir SN, Wani AA. Naringenin protects HaCaT human keratinocytes against UVB-induced apoptosis and enhances the removal of cyclobutane pyrimidine dimers from the genome. *Photochem Photobiol.* ***2008*** *Mar-Apr;84(2):307-16.*
2. Zhao Q, Barakat BM, Qin S, Ray A, El-Mahdy MA, Wani G, **Arafa el-S**, Mir SN, Wang QE, Wani AA. The p38 mitogen-activated protein kinase augments nucleotide excision repair by mediating DDB2 degradation and chromatin relaxation. *J Biol Chem.* ***2008*** *Nov 21; 283(47):32553-61*.
3. **Arafa el-SA**, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, Wani AA. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. *Cancer Res.* ***2009*** *Dec 1; 69(23):8910-7.*
4. Barakat BM, Wang QE, Han C, Milum K, Yin DT, Zhao Q, Wani G, **Arafa el-SA**, El-Mahdy MA, Wani AA. Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis. *Int J Cancer.* ***2010*** *Aug 15; 127(4):977-88.*
5. **Arafa el-SA**, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, El-Mahdy MA, Wani AA. [Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells.](http://www.ncbi.nlm.nih.gov/pubmed/21040738) *Mutat Res*. ***2011*** *Jan 10; 706(1-2):28-35.*
6. Mehany HA, Abo Youssef AM, Ahmed LA, **Arafa el-SA,** Abd El-Latif HA. Protective effect of vitamin E and atorvastatin against potassium dichromate-induced nephrotoxicity in rats. Beni-Suef University Journal of Basic and Applied Sciences. June ***2013***, [2 (2](http://www.sciencedirect.com/science/journal/23148535/2/2)); 96–102.
7. [Omar](https://www.researchgate.net/researcher/15922186_Hany_A_Omar/) H, [Salama](https://www.researchgate.net/researcher/81165151_Samir_A_Salama/" \o "Samir A. Salama) S, **Arafa el-SA**, Weng [J-R](https://www.researchgate.net/researcher/38160341_Jing-Ru_Weng/). Antitumor effects of energy restriction-mimetic agents: thiazolidinediones.  [Biological Chemistry](https://www.researchgate.net/journal/0021-9258_Journal_of_Biological_Chemistry) ***2013*** Jul; 394(7):865-70.
8. Omar HA, **Arafa el-SA**, Salama SA, Arab HH, Wu CH, Weng JR. [OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.](http://www.ncbi.nlm.nih.gov/pubmed/23921148) Toxicol Appl Pharmacol. ***2013*** Nov 1; 272(3):616-24.
9. Omar HA, **Arafa el-SA**, Maghrabi IA, Weng JR. Sensitization of Hepatocellular Carcinoma Cells to Apo2L/TRAIL by a Novel Akt/NF-κB Signaling Inhibitor. Basic Clin Pharmacol Toxicol. ***2014*** Jun; 114(6):464-71.
10. **Arafa el-SA**, Abdelazeem AH, Arab HH, Omar HA. OSU-CG5, a Novel Energy Restriction Mimetic Agent Targets The Colorectal Cancer Cells. Acta Pharmacol Sin.  ***2014*** Mar; 35(3):394-400.
11. Gouda AM, Abdelazeem AH, **Arafa el-SA**, Abdellatif KR. Design, Synthesis and Pharmacological Evaluation of Novel Pyrrolizine Derivatives as Potential Anticancer Agents. Bioorg Chem. ***2014*** Apr; 53:1-7.
12. Hemeida RA, Abdel-Raheem IT, El-Sherbiny GA, **Arafa el-SA**, Abdel-Gawad AS. Candesartan Modulates the Antioxidant Effect of Silymarin Against CCl4-Induced Liver Injury in Rats. Free Radicals and Antioxidants, ***2014***; 4(1):32-38.
13. Arab HH, Salama SA, Eid AH, Omar HA, **Arafa el-SA**, Maghrabi IA. Camel’s milk ameliorates TNBS-induced colitis in rats via downregulation of inflammatory cytokinesand oxidative stress. Food Chem Tox, ***2014*** Apr 28; 69C:294-302.
14. Rateb ME, Hassan HM, **Arafa el-SA**, Jaspars M, Ebel R. Decorosides A and B, cytotoxic flavonoid glycosides from the leaves of Rhododendron decorum. Natural Product Communications, ***2014***. 9(4):473-476.
15. Mohamed WR, **Arafa el-SA**, Shehata BA, El Sherbiny GA, Elgendy AM, Beneficial effects of hesperidin against cisplatin-induced nephrotoxicity and oxidative stress in rats. British Journal of Pharmacology and Toxicology, 2014 Dec.
16. Arab HH, Salama SA, Omar HA, **Arafa el-SA**, Maghrabi IA. [Diosmin Protects against Ethanol-Induced Gastric Injury in Rats: Novel Anti-Ulcer Actions.](http://www.ncbi.nlm.nih.gov/pubmed/25821971) PLoS One. 2015 Mar 30;10(3)

## **Attended Conferences and Workshops**

* Comprehensive Cancer Center 9th Annual Scientific Meeting―Columbus, Ohio, USA. February 2007.
* 9th Annual Midwest DNA Repair Symposium―Lewis Center, Ohio, USA. May 2007.
* Comprehensive Cancer Center 10th Annual Scientific Meeting―Columbus, Ohio, USA. February 2008.
* American Association for Cancer Research 99th Annual meeting―San Diego, California, USA. April 2008.
* 10th Annual Midwest DNA Repair Symposium―Pittsburgh, Pennsylvania, USA. May 2008.
* Comprehensive Cancer Center 12th Annual Scientific Meeting―Columbus, Ohio, USA. February 2010.
* Recent Advances in pharmaceutical Research- Beni-Suef University, Egypt. January 2011.
* Biovision: 7th edition of the international life sciences forum―Lyon, France. March 2011.
* The Pharmacist’s Role in Achieving Healthcare Outcomes- MIU University, Egypt. March 2012
* American Association for Cancer Research, Molecular Targeted Therapies: Mechanisms of Resistance―San Diego, California, USA. May 2012.
* How to Design and Interpret a Medical Survey – Taif University – Taif, KSA. October 2013.
* Developing Research Abilities: Idea Formulation and Research Management – King Abdulaziz City for Science and Technology, KSA. November 2013.
* Fifth Laboratory and Blood Bank Awareness - Taif University – Taif, KSA. February 2014.
* Eighth Dubai International Conference for Medical Sciences – Dubai, UAE. December 2014.
* Twentieth Dubai International Pharmaceuticals and Technologies Conference and Exhibition – Dubai, UAE. March 2015.
* Diabetes and the Eye – Rashid Centre for Diabetes and Research, Ajman, UAE. March 2015.

## **References**

* **Prof. Dr. Altaf. A. Wani**  Professor of Biochemistry and Division Chief of Radiobiology, Radiobiology Department, The Ohio State University, USA.

Tel: +1-614 292 9015; Fax: 614 292 9102 E-mail: [wani.2@osu.edu](mailto:wani.2@osu.edu)

* **Prof. Dr. Mohamed A. El-Mahdy**  Professor and research associate, Davis Heart and Lung Research Institute, The Ohio state University, USA. Tel: +1-614 292 2367

E-mail: [mohamed.el-mahdy@osumc.edu](mailto:mohamed.el-mahdy@osumc.edu)

* Prof. Dr. Samira Saleh Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Egypt. Tel.: +201001464334, Fax: +202  287  6271 E-Mail: [samirasaleh7@gmail.com](mailto:samirasaleh7@gmail.com)
* **Prof. Dr. Hekma A. Abd El-Latif** Professor of Pharmacology and Toxicology department, Faculty of Pharmacy, Umm Al-Qura University, Saudi Arabia. Cell.: +966-544655731

E-Mail: [abdeltawabhekma@yahoo.co.uk](mailto:abdeltawabhekma@yahoo.co.uk)